# Cellectar Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cellectar Biosciences, Inc.). ## Overview Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing cancer therapies built on its proprietary phospholipid ether drug conjugate (PDC) delivery platform. The company is trying to use that platform to direct payloads more selectively to cancer cells, with the goal of improving efficacy while reducing off-target toxicity. Its pipeline includes iopofosine and other PDC-based candidates such as CLR 121125 and CLR 121225, and it also pursues collaborations to expand the platform into additional oncology modalities. Cellectar is still in the development stage and does not yet have a commercial product business, so its value proposition is centered on clinical progress, regulatory execution, and strategic partnerships. ## Products & services • PDC™ cancer-targeting drug delivery platform • Iopofosine and related oncology candidates • CLR 121125 and CLR 121225 pipeline programs • Preclinical PDC payload and linker programs • R&D collaborations and co-development agreements - **Clinical oncology candidates** (55%) — Late-stage and clinical-stage cancer drug candidates built on the PDC platform, including iopofosine and related programs. - **Preclinical pipeline** (20%) — Earlier-stage PDC programs using novel payloads, linkers, peptides, and oligonucleotides. - **Platform technology licensing and collaborations** (15%) — Research collaborations and co-development arrangements that extend the PDC platform with third-party technologies. - **Drug development services and support** (10%) — Internal and outsourced development activities supporting clinical, manufacturing, and regulatory work. - PDC™ cancer-targeting drug delivery platform - Iopofosine and related oncology candidates - CLR 121125 and CLR 121225 pipeline programs - Preclinical PDC payload and linker programs - R&D collaborations and co-development agreements ## Customers Cellectar does not sell commercial products today, so its near-term 'customers' are primarily research collaborators, clinical investigators, regulators, and future oncology treatment providers rather than end-market patients. In a commercial scenario, the company’s products would be used by physicians and oncology centers treating cancers that may respond to targeted delivery of cytotoxic or radiopharmaceutical payloads. The company also depends on contract research organizations, contract manufacturers, and specialized suppliers such as AtomVie and SpectronRx to execute its development program. Because the business is still pre-commercial, adoption will depend on physician education, clinical evidence, and regulatory approval rather than traditional customer demand. - **Oncology physicians and treatment centers** (primary) — Would use approved PDC-based cancer therapies if clinical data and labeling support adoption; they buy for efficacy and safety advantages. - **Pharmaceutical and biotech collaborators** (primary) — Partner with Cellectar to combine the PDC platform with payloads, linkers, or radioisotopes to expand the pipeline. - **Clinical trial sites and investigators** (secondary) — Run studies for iopofosine and other candidates and are essential to generating the data needed for approval. - **CROs and CMOs** (primary) — Provide outsourced research, clinical, and manufacturing services that Cellectar relies on because it has closed manufacturing operations. - Oncology physicians and cancer centers that would prescribe approved therapies - Clinical investigators and trial sites running Cellectar-sponsored studies - Pharmaceutical collaborators seeking access to the PDC platform - Contract research organizations supporting development and regulatory work - Contract manufacturers and radiopharmaceutical supply partners enabling clinical supply ## Geography Cellectar is headquartered in the United States, with principal executive offices in Florham Park, New Jersey, and its shares listed on Nasdaq Capital Market. The company has closed its former manufacturing operations in Wisconsin and now relies on outsourced facilities and third-party partners for research, development, and manufacturing. Its patent filings are intended for key commercial markets worldwide, reflecting an ambition to protect the platform across major oncology markets rather than in one domestic geography. Because the company is still pre-commercial, geography matters mainly through where trials are run, where partners are located, and where future regulatory approvals and patent protection can be secured. - Headquartered in Florham Park, New Jersey, United States - Former manufacturing operations were closed in Wisconsin - Relies on third-party facilities for R&D and manufacturing support - Patent applications are filed in key commercial markets worldwide - Future commercialization would depend on approvals in the U.S., Europe, and other markets ## Strategy Cellectar’s strategy is centered on advancing its PDC platform through clinical development, with the goal of proving that targeted delivery can improve cancer treatment outcomes. The company is also broadening the platform through collaborations that add new payloads, linkers, and radioisotope approaches, which could expand the number of addressable indications. Management has stated that it is exploring strategic alternatives, including partnerships, licensing, mergers, acquisitions, and other transactions, to advance the platform and pipeline. Given its limited liquidity, capital preservation and external financing are also core strategic priorities because they determine how long the company can fund development work. - **Advance late-stage oncology candidates** (short-term) — Clinical proof-of-concept and regulatory progress are the main drivers of value for a pre-commercial biopharma company. - **Expand the platform through collaborations** (medium-term) — Partnering can add payload diversity and reduce internal development burden while broadening the pipeline. - **Secure additional capital or strategic transactions** (short-term) — The company has limited liquidity and needs funding to continue operations and clinical development. - Advance iopofosine and other PDC candidates through clinical development - Use the PDC platform to target cancer cells more selectively and reduce off-target toxicity - Expand the pipeline through collaborations with technology partners - Explore strategic alternatives to accelerate development and create value - Preserve cash through outsourcing and cost-saving measures ## Risks Cellectar faces the classic risks of a development-stage biopharmaceutical company: clinical failure, regulatory delay, and uncertainty that any candidate will prove safe and effective in humans. Its dependence on third-party CROs, CMOs, and specialized suppliers creates execution risk because delays, compliance issues, or capacity problems can slow trials and manufacturing. The company also has substantial going-concern and financing risk because it expects continuing operating losses and may need additional capital or a strategic transaction to fund operations beyond the near term. More broadly, oncology drug development is highly competitive, physician adoption can be slow, and alternative therapies may limit market acceptance even if products are approved. - **Clinical and regulatory failure** [critical] — The company must prove that each candidate is safe and effective and obtain regulatory approval before commercialization. - **Going-concern and financing risk** [critical] — Management disclosed limited liquidity and the need for additional capital or strategic alternatives to fund operations. - **Third-party manufacturing and CRO dependence** [high] — The company relies on outsourced partners for research, clinical studies, and drug supply, so partner failures can delay programs. - **Commercial adoption risk** [medium] — Even if approved, physicians may prefer established oncology therapies and require substantial education before adopting new products. - Clinical development may fail to show safety or efficacy in target indications - FDA or other regulatory review may delay or reject product candidates - Dependence on CROs, CMOs, and suppliers can disrupt trials or manufacturing - Limited liquidity creates going-concern and financing risk - Competition from established oncology therapies may limit adoption - Physician education and market acceptance may take longer than expected ## Accounting The most important accounting issue for Cellectar is the judgment involved in accruing research, clinical, manufacturing, and professional service costs, because much of the company’s spending is outsourced and invoiced in arrears. That makes period-end estimates sensitive to the timing and completeness of CRO, investigator, and manufacturing invoices, which can shift reported R&D expense between quarters. Because the company is pre-revenue and development-stage, operating losses and cash burn are central to the financial statements, and going-concern disclosure is a major analytical focus. Investors should also watch for valuation and remeasurement effects from equity securities and any future financing instruments, since other income/expense can be affected by non-operating fair value changes and interest income. - **Accrued clinical and manufacturing costs** — Can materially affect quarterly R&D expense and liabilities - **Going-concern assessment** — Important for assessing solvency and continuity of operations - **Fair value remeasurement of equity securities** — Can create volatility below operating income - Accrued liabilities depend on estimating outsourced clinical and manufacturing services - R&D expense can shift between quarters based on trial timing and invoice receipt - Going-concern disclosure reflects limited liquidity and expected future losses - Equity security remeasurement can affect other income/expense - Cash burn and capital raises are key to interpreting reported results --- *Last updated: 2026-04-28T14:26:13.035991+00:00*